Literature DB >> 14551175

CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans.

Héctor M Gonzalez1, Elba M Romero, A Aaron Peregrina, Teresa de J Chávez, Estanislao Escobar-Islas, Felipe Lozano, Carlos Hoyo-Vadillo.   

Abstract

Omeprazole has been used as a drug probe for CYP2C19, but no systematic data are available for Mexican populations. The aim of this study was to evaluate the phenotype frequencies of the CYP2C19 polymorphism in West Mexicans. Besides omeprazole, sulfone was measured to evaluate CYP3A4 after administration of the 20-mg dose to 127 healthy volunteers. Logarithms of metabolic indexes of omeprazole/hydroxyomeprazole for CYP2C19 and omeprazole/omeprazole sulfone for CYP3A4 had trimodal distributions. Five subjects (4%) had a log CYP2C19 metabolic index below -0.9, suggesting an ultra-extensive phenotype. Poor metabolizers (log metabolic index > 0.6) were 6%. For CYP3A4, 11 subjects (9%) were below -0.3 of the log metabolic index. The log metabolic index of omeprazole/omeprazole sulfone was above the antimode of 0.6 for 11% of this population. The mean log metabolic index of CYP3A4 extensive metabolizers (80%) was 0.166, which seems to be higher than the data described for Caucasians and lower than that for Asians.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551175     DOI: 10.1177/0091270003258170

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  15 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in South Indians.

Authors:  J Rosemary; C Adithan; N Padmaja; C H Shashindran; N Gerard; R Krishnamoorthy
Journal:  Eur J Clin Pharmacol       Date:  2005-01-21       Impact factor: 2.953

3.  Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4.

Authors:  Ylva Böttiger
Journal:  Eur J Clin Pharmacol       Date:  2006-06-22       Impact factor: 2.953

4.  Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.

Authors:  V Michaud; E Ogburn; N Thong; A O Aregbe; T C Quigg; D A Flockhart; Z Desta
Journal:  Clin Pharmacol Ther       Date:  2012-02-08       Impact factor: 6.875

5.  Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotype.

Authors:  Alma Faviola Favela-Mendoza; Gabriela Martinez-Cortes; Marcelo Hernandez-Zaragoza; Joel Salazar-Flores; Jose Francisco Muñoz-Valle; Victor Manuel Martinez-Sevilla; Noemi Yolanda Velazquez-Suarez; Hector Rangel-Villalobos
Journal:  J Genet       Date:  2015-03       Impact factor: 1.166

6.  Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients.

Authors:  Vera Lucia Lanchote; Roque Almeida; Aldina Barral; Manoel Barral-Netto; Maria Paula Marques; Natália V Moraes; Angela M da Silva; Tania M V Souza; Guilherme Suarez-Kurtz
Journal:  Br J Clin Pharmacol       Date:  2015-07-02       Impact factor: 4.335

7.  Possible interethnic differences in omeprazole pharmacokinetics : comparison of Jordanian Arabs with other populations.

Authors:  Sireen Shilbayeh; Maha F Tutunji
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  Buspirone, fexofenadine, and omeprazole: quantification of probe drugs and their metabolites in human plasma.

Authors:  Parul Gor; Yazen Alnouti; Gregory A Reed
Journal:  J Pharm Biomed Anal       Date:  2011-04-09       Impact factor: 3.935

9.  Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers.

Authors:  Adriana Rocha; Eduardo B Coelho; Soraia A P Moussa; Vera L Lanchote
Journal:  Eur J Clin Pharmacol       Date:  2008-06-26       Impact factor: 2.953

10.  Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico.

Authors:  Joel Salazar-Flores; Luis A Torres-Reyes; Gabriela Martínez-Cortés; Rodrigo Rubi-Castellanos; Martha Sosa-Macías; José F Muñoz-Valle; César González-González; Angélica Ramírez; Raquel Román; José L Méndez; Andrés Barrera; Alfredo Torres; Rafael Medina; Héctor Rangel-Villalobos
Journal:  Genet Test Mol Biomarkers       Date:  2012-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.